Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Dose-exploration Study, Followed by a Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Efficacy and Safety of CVL237 Tablets in Patients With APDS/PASLI

NCT06293716 is registered in ClinicalTrials.gov with Convalife (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06293716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06293716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Dose-exploration Study, Followed by a Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Efficacy and Safety of CVL237 Tablets in Patients With APDS/PASLI
Lead sponsor
Convalife (Shanghai) Co., Ltd.
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 30, 2024
Completion date
March 30, 2026
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pi3k and p110delta hyperactivation syndrome